Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Specimen Handling 2Biopsy 2pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1infigratinib 1enfortumab vedotin 1durvalumab 1Vinblastine 1Surgical Procedures, Operative 1Platinum 1Nephroureterectomy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Nephroureterectomy × Genitourinary × Clear all
NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
21 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡